Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1989 Jan 14;298(6666):82–86. doi: 10.1136/bmj.298.6666.82

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

D Rachmilewitz 1
PMCID: PMC1835436  PMID: 2563951

Abstract

OBJECTIVE--To assess the safety and efficacy of a preparation of mesalazine (5-aminosalicylic acid) coated with a pH dependent resin (Eudragit L) as compared with sulphasalazine in patients with active mild to moderate ulcerative colitis. DESIGN--Eight week randomised double blind parallel group study. SETTING--Forty six gastroenterology outpatient clinics in seven countries. PATIENTS--Two hundred and twenty patients aged 18-70 who met the following criteria: clinical activity index greater than or equal to 6 and endoscopic index greater than or equal to 4; no concomitant treatment for ulcerative colitis; no hypersensitivity to salicylates or sulphonamides. Of the 164 patients eligible for efficacy analysis, 87 received the coated preparation of mesalazine and 77 sulphasalazine. Most of the remaining patients (28 in each group) were ineligible for the efficacy analysis because of treatment with steroid enemas. All pretrial characteristics were comparable in the two treatment groups. INTERVENTIONS--Coated mesalazine (Mesasal) 1.5 g daily or sulphasalazine 3.0 g daily for eight weeks. Compliance monitored by pill counts. END POINT--Clinical and endoscopic remission. MEASUREMENTS AND MAIN RESULTS--Clinical activity measured by daily diary cards, assessment by investigators, and laboratory findings. Endoscopic evaluation at week 8. After four weeks 50 of 70 patients (71%) taking coated mesalazine and 38 of 58 (66%) taking sulphasalazine had achieved remission of their disease by eight weeks remission rates were 74% (37/50 patients) and 81% (35/43) in the two treatment groups respectively. Endoscopic remission at eight weeks was recorded in 20 of 41 patients (49%) taking coated mesalazine and 18 of 38 (47%) taking sulphasalazine. There was a higher incidence of adverse events among patients taking sulphasalazine (25/105; 24%) than among those taking coated mesalazine (16/115; 14%). CONCLUSION--Mesalazine coated with Eudragit L is a safe, logical alternative to sulphasalazine.

Full text

PDF
82

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  2. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
  3. Collins J. R. Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis. South Med J. 1968 Apr;61(4):354–358. doi: 10.1097/00007611-196804000-00005. [DOI] [PubMed] [Google Scholar]
  4. Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
  5. Dew M. J., Harries A. D., Evans B. K., Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine. Lancet. 1983 Oct 1;2(8353):801–801. doi: 10.1016/s0140-6736(83)92341-3. [DOI] [PubMed] [Google Scholar]
  6. Dew M. J., Hughes P. J., Lee M. G., Evans B. K., Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982 Sep;14(3):405–408. doi: 10.1111/j.1365-2125.1982.tb01999.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Donald I. P., Wilkinson S. P. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine. Postgrad Med J. 1985 Dec;61(722):1047–1048. doi: 10.1136/pgmj.61.722.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gulley R. M., Mirza A., Kelly C. E. Hepatotoxicity of salicylazosulfapyridine: a case report and review of the literature. Am J Gastroenterol. 1979 Nov;72(5):561–564. [PubMed] [Google Scholar]
  10. Hardy J. G., Healey J. N., Reynolds J. R. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1987 Aug;1(4):273–280. doi: 10.1111/j.1365-2036.1987.tb00627.x. [DOI] [PubMed] [Google Scholar]
  11. Jamshidi K., Arlander T., Garcia M. C., Windschitl H. W., Swaim W. R. Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis. Minn Med. 1972 Jun;55(6):545–548. [PubMed] [Google Scholar]
  12. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  13. Lennard-Jones J. E. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut. 1977 Jan;18(1):69–72. doi: 10.1136/gut.18.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Levi A. J., Fisher A. M., Hughes L., Hendry W. F. Male infertility due to sulphasalazine. Lancet. 1979 Aug 11;2(8137):276–278. doi: 10.1016/s0140-6736(79)90292-7. [DOI] [PubMed] [Google Scholar]
  15. Ligumsky M., Karmeli F., Sharon P., Zor U., Cohen F., Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981 Sep;81(3):444–449. [PubMed] [Google Scholar]
  16. Miller B. Nebenwirkungen der Therapie mit Salazosulfapyridin. Dtsch Med Wochenschr. 1980 Nov 14;105(46):1596–1597. doi: 10.1055/s-2008-1070919. [DOI] [PubMed] [Google Scholar]
  17. O'Moráin C., Smethurst P., Doré C. J., Levi A. J. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984 Oct;25(10):1078–1084. doi: 10.1136/gut.25.10.1078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Peskar B. M., Dreyling K. W., Peskar B. A., May B., Goebell H. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions. 1986 Jun;18(3-4):381–383. doi: 10.1007/BF01965001. [DOI] [PubMed] [Google Scholar]
  19. Pounder R. E., Craven E. R., Henthorn J. S., Bannatyne J. M. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. Gut. 1975 Mar;16(3):181–185. doi: 10.1136/gut.16.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988 May;29(5):669–674. doi: 10.1136/gut.29.5.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sandberg-Gertzén H., Järnerot G., Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986 Apr;90(4):1024–1030. doi: 10.1016/0016-5085(86)90882-6. [DOI] [PubMed] [Google Scholar]
  22. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629. doi: 10.1056/NEJM198712243172603. [DOI] [PubMed] [Google Scholar]
  23. Selby W. S., Barr G. D., Ireland A., Mason C. H., Jewell D. P. Olsalazine in active ulcerative colitis. Br Med J (Clin Res Ed) 1985 Nov 16;291(6506):1373–1375. doi: 10.1136/bmj.291.6506.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shaffer J. L., Kershaw A., Berrisford M. H. Sulphasalazine-induced infertility reversed on transfer to 5-aminosalicylic acid. Lancet. 1984 Jun 2;1(8388):1240–1240. doi: 10.1016/s0140-6736(84)91724-0. [DOI] [PubMed] [Google Scholar]
  25. Sharon P., Stenson W. F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984 Mar;86(3):453–460. [PubMed] [Google Scholar]
  26. Singleton J. W., Law D. H., Kelley M. L., Jr, Mekhjian H. S., Sturdevant R. A. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 1979 Oct;77(4 Pt 2):870–882. [PubMed] [Google Scholar]
  27. Taffet S. L., Das K. M. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983 Sep;28(9):833–842. doi: 10.1007/BF01296907. [DOI] [PubMed] [Google Scholar]
  28. van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES